Precision Antibody-Based Therapeutics for Complement Regulation

Time: 3:00 pm
day: Track A - Day 1 PM


  • Targeting critical components of the complement pathway can impact diseases that are initiated or
    exacerbated by complement dysregulation
  • Antibody based therapeutics can be used to precisely target and potently inhibit complement activation
  • Visterra has developed novel antibodies for targeting complement activation